stockrowCharles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. (CRL) Return on assets
Charles River Laboratories International, Inc.'s return on assets over the twelve months to 30 September 2026 was 0.54%, up 2.5 percentage points from fiscal 2025 (−1.97%). Over the past ten years it has ranged from −1.97% (fiscal 2025) to 7.58% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −1.97% | (2.10) |
| FY2024 | 0.13% | (5.88) |
| FY2023 | 6.01% | (0.64) |
| FY2022 | 6.65% | 0.40 |
| FY2021 | 6.25% | (0.90) |
| FY2020 | 7.15% | 1.25 |
| FY2019 | 5.90% | (0.77) |
| FY2018 | 6.67% | 2.30 |
| FY2017 | 4.37% | (2.11) |
| FY2016 | 6.48% | (1.10) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 25.5% |
| ILMN Illumina, Inc. compare | 13.8% |
| QGEN QIAGEN N.V. compare | 6.99% |
| DGX Quest Diagnostics Incorporated compare | 6.73% |
| LH Labcorp Holdings Inc. compare | 5.40% |
| ICLR ICON PLC compare | 2.74% |
| RVTY Revvity Inc. compare | 2.14% |
| CRL Charles River Laboratories International, Inc. | 0.54% |
| GH Guardant Health, Inc. compare | −30.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement